An official website of the United States government
Home
Name
Posluma
Alternate Names
Flotufolastat F18
Abbreviations
None
Category
Other therapy
Subcategory
NSC Number
None
Primary Site
Prostate
Histology
None
Remarks
Informational only. Do not code as treatment. New imaging agent.
June 2, 2023
The FDA approved Posluma (flotufolastat F 18), an optimized, high-affinity radiohybrid Prostate-Specific Membrane Antigen-targeted PET imaging agent. Posluma is indicated for positron emis¬sion tomography of prostate-specific membrane antigen-positive lesions in men with prostate cancer with sus¬pected metastasis who are candidates for initial definitive therapy or with sus¬pected recurrence based on elevated serum prostate-specific antigen level.
June 2, 2023
The FDA approved Posluma (flotufolastat F 18), an optimized, high-affinity radiohybrid Prostate-Specific Membrane Antigen-targeted PET imaging agent. Posluma is indicated for positron emis¬sion tomography of prostate-specific membrane antigen-positive lesions in men with prostate cancer with sus¬pected metastasis who are candidates for initial definitive therapy or with sus¬pected recurrence based on elevated serum prostate-specific antigen level.
Coding
This drug should NOT be coded
